Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways

Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways

BackgroundTargeting immune checkpoints for HIV treatment potentially provides a double benefit resulting from the ability to restore viral-specific CD8+ T-cell functions and enhance HIV production from reservoir cells. Despite promising pre-clinical data, PD-1 blockade alone in HIV-1-infected patien...

Full description

Bibliographic Details
Main Authors:	Jing Li, Hui-Huang Huang, Bo Tu, Ming-Ju Zhou, Wei Hu, Yu-Long Fu, Xiao-Yu Li, Tao Yang, Jin-Wen Song, Xing Fan, Yan-Mei Jiao, Ruo-Nan Xu, Ji-Yuan Zhang, Chun-Bao Zhou, Jin-Hong Yuan, Cheng Zhen, Ming Shi, Fu-Sheng Wang, Chao Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Series:	Frontiers in Immunology
Subjects:	PD-1+CD39+ CD8+ T cells HIV-1 cytotoxic T cells PD-1/PD-L1 CD39/adenosine pathway
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.687296/full

Similar Items

Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer
by: Bremer, E., et al.
Published: (2022)

Avaliação da influência das moléculas PD-1, CD39 e CD73 na imunomodulação induzida pela infecção com a bactéria Brucella Abortus
by: Melo, Juliana
Published: (2017)

Rôle de l’éctonucléotidase CD39 dans l’acquisition d’un phénotype immunorégulateur par les macrophages associés aux tumeurs
by: D'Almeida, Sénan
Published: (2015)

Targeting adenosine for cancer immunotherapy
by: Robert D. Leone, et al.
Published: (2018-06-01)

Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML
by: F. Brauneck, et al.
Published: (2021-01-01)

Skewed CD39/CD73/adenosine pathway in B cells is associated with innate immune hyperactivation in chronic HIV-1 infection
by: Wen-Xian Chang, et al.
Published: (2019-02-01)

Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1
by: Jing-Jing Wang, et al.
Published: (2019-11-01)

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
by: Fanqiao Meng, et al.
Published: (2020-08-01)

Effect of a kind of Chinese herbal compound on the expression of PD-1/PD-L1 in spleen lymphocytes of mice
by: Yingze WANG, et al.
Published: (2019-02-01)

Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy
by: Yihang Qi, et al.
Published: (2021-01-01)

Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis
by: Rafael de Freitas e Silva, et al.
Published: (2020-10-01)

Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
by: Fan Luo, et al.
Published: (2021-08-01)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2021-09-01)

The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8+ T Cells During an Acute Retroviral Infection
by: Paul David, et al.
Published: (2019-02-01)

Characterization of impaired CD8+ T cell responses to Chlamydia trachomatis
by: Fankhauser, Sarah Carmela
Published: (2013)

Human CD8+HLA-DR+ Regulatory T Cells, Similarly to Classical CD4+Foxp3+ Cells, Suppress Immune Responses via PD-1/PD-L1 Axis
by: Andres Machicote, et al.
Published: (2018-11-01)

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
by: Yu-Hung Lee, et al.
Published: (2021-02-01)

The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection
by: Kristen E. Pauken, et al.
Published: (2020-06-01)

Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma
by: Marco Tucci, et al.
Published: (2018-02-01)

PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4<sup>+</sup> T Cells
by: Iga Jancewicz, et al.
Published: (2021-08-01)

PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
by: Sandra Lassalle, et al.
Published: (2020-11-01)

Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers
by: Joana Vitallé, et al.
Published: (2018-07-01)

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
by: Marije Baas, et al.
Published: (2016-01-01)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
by: Miren Zuazo, et al.
Published: (2020-11-01)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
by: Federica Costa, et al.
Published: (2021-01-01)

Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer
by: Enrico Munari, et al.
Published: (2021-05-01)

Downregulation of CD73 associates with T cell exhaustion in AML patients
by: Yaxian Kong, et al.
Published: (2019-04-01)

Inhibitory Molecules PD-1, CD73 and CD39 Are Expressed by CD8+ T Cells in a Tissue-Dependent Manner and Can Inhibit T Cell Responses to Stimulation
by: Corinne J. Smith, et al.
Published: (2021-07-01)

Circulating and Tumor-Infiltrating NK Cells From Clear Cell Renal Cell Carcinoma Patients Exhibit a Predominantly Inhibitory Phenotype Characterized by Overexpression of CD85j, CD45, CD48 and PD-1
by: Andrea Ziblat, et al.
Published: (2021-06-01)

Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ γδT Cells a Unique Lymphocyte Subset
by: Jasper Nörenberg, et al.
Published: (2021-02-01)

PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis
by: Cheryl L. Day, et al.
Published: (2018-08-01)

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
by: Jun Wang, et al.
Published: (2017-01-01)

PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis
by: Shwetank, et al.
Published: (2019-04-01)

Increased expression of PD-1 on CD4+ T cells subsets in Rheumatoid Arthritis patients
by: faezeh ajam, et al.
Published: (2019-07-01)

PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression
by: Francesca R. Mariotti, et al.
Published: (2019-03-01)

Proteomic Implications of Tumoral Infiltrating Lymphocytes in Melanoma: PD-L1, CD4 and CD8 - Short Review
by: Antonela Nicolau Anca, et al.
Published: (2020-08-01)

Serum sCD25 Protein as a Predictor of Lack of Long-Term Benefits from Immunotherapy in Non-Small Cell Lung Cancer: A Pilot Study
by: Anna Siemiątkowska, et al.
Published: (2021-07-01)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
by: Christie P. M. Verkleij, et al.
Published: (2020-12-01)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
by: Maite Alvarez, et al.
Published: (2020-02-01)

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial
by: Anne Gomez-Brouchet, et al.
Published: (2017-09-01)